DXCM DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCM

Core Viewpoint - Rosen Law Firm is reminding investors of DexCom, Inc. about the upcoming deadline for a securities class action lawsuit, encouraging them to secure legal counsel before December 29, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025, and can join by submitting a form or contacting the law firm [3][6]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues, leading to increased regulatory scrutiny and potential legal repercussions [5].